RELATIONSHIP BETWEEN ANTIDEPRESSANT RESPONSE AND PLASMA-CONCENTRATIONS OF FLUOXETINE AND NORFLUOXETINE

被引:51
作者
NORMAN, TR
GUPTA, RK
BURROWS, GD
PARKER, G
JUDD, FK
机构
[1] ROYAL CANBERRA HOSP,GARAN,ACT 2606,AUSTRALIA
[2] UNIV NEW S WALES,PRINCE WALES HOSP,SCH PSYCHIAT,RANDWICK,NSW 2031,AUSTRALIA
关键词
CLINICAL EFFECT; FLUOXETINE; HPLC; NORFLUOXETINE; PLASMA CONCENTRATION;
D O I
10.1097/00004850-199300810-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relationship between plasma concentration, clinical outcome and side-effects was examined in 23 patients with major depressive disorder (DSM-III-R) treated with fluoxetine. All patients received a fixed dose of 20 mg for 6 weeks. Good response was observed in 57% of patients, while 30% of patients had moderate responses after 6 weeks of treatment. Fluoxetine and norfluoxetine plasma concentrations were not significantly influenced by age and sex. At 6 weeks, plasma fluoxetine concentrations were not significantly different between responders and non-responders to treatment (82.2 +/- 59.6 mug/l vs. 84.7 +/- 6.7 mug/1) or those with or without side-effects (74.6 +/- 28.7 mug/l vs. 87.0 +/- 66.6 mug/1). Similarly, norfluoxetine concentrations were not significantly different for responders and non-responders (65.5 +/- 28.9 mug/l vs. 66.5 +/- 26.2 mug/l) or those with or without side-effects (66.6 +/- 14.4 mug/l vs. 61.5 +/- 33.6 mug/l). Plasma concentrations and clinical outcome were not related in a simple manner. Further studies are needed to evaluate the role of monitoring plasma fluoxetine/norfluoxetine concentrations as a routine procedure.
引用
收藏
页码:25 / 29
页数:5
相关论文
共 50 条
[21]   A rapid HPLC-DAD method for the analysis of fluoxetine and norfluoxetine in plasma from overdose patients [J].
Sabbioni, C ;
Bugamelli, F ;
Varani, G ;
Mercolini, L ;
Musenga, A ;
Saracino, MA ;
Fanali, S ;
Raggi, MA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 36 (02) :351-356
[22]   Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography mass spectrometry [J].
Eap, CB ;
Gaillard, N ;
Powell, K ;
Baumann, P .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 682 (02) :265-272
[23]   Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection [J].
Raggi, MA ;
Mandrioli, R ;
Casamenti, G ;
Bugamelli, F ;
Volterra, V .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 18 (1-2) :193-199
[24]   Determination of Fluoxetine and Norfluoxetine by UFLC- MS/MS in Human Plasma and its Application to Pharmacokinetic Study [J].
Ma, Jing ;
Liu, Ran ;
Lv, Chunxiao ;
Qi, Huihong ;
Fan, Ruoxi ;
Bi, Kaishun ;
Li, Qing .
LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (10) :1485-1492
[25]   Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study [J].
Ni, Xiao-Jia ;
Wang, Zhan-Zhang ;
Shang, De-Wei ;
Lu, Hao-Yang ;
Zhang, Ming ;
Wen, Yu-Guan .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2018, 1092 :506-514
[26]   Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients [J].
Llerena, A ;
Dorado, P ;
Berecz, R ;
González, A ;
Norberto, MJ ;
de la Rubia, A ;
Cáceres, M .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 783 (01) :25-31
[27]   Determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by liquid chromatography-tandem mass spectrometry [J].
R. Green ;
R. Houghton ;
J. Scarth ;
C. Gregory .
Chromatographia, 2002, 55 (Suppl 1) :S133-S136
[28]   PLASMA-CONCENTRATIONS OF BUPIVACAINE IN CELIAC PLEXUS BLOCK [J].
WULF, H ;
GLEIM, M ;
MAIER, C ;
SCHULZECK, S .
REGIONAL ANESTHESIA, 1995, 20 (03) :222-226
[29]   Formation of inclusion-complexes between cyclodextrins, as mobile-phase additives in RPTLC, and fluoxetine, norfluoxetine, and promethazine [J].
Lambroussi, V ;
Piperaki, S ;
Tsantili-Kakoulidou, A .
JPC-JOURNAL OF PLANAR CHROMATOGRAPHY-MODERN TLC, 1999, 12 (02) :124-128
[30]   Determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by liquid chromatography-tandem mass spectrometry [J].
Green, R ;
Houghton, R ;
Scarth, J ;
Gregory, C .
CHROMATOGRAPHIA, 2002, 55 :S133-S136